查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2007793

合成生物学平台市场预测至2034年—按类型、应用、最终用户和地区分類的全球分析

Synthetic Biology Platforms Market Forecasts to 2034- Global Analysis By Type (DNA Synthesis Platforms, Gene Editing Platforms, Protein Engineering Platforms and Metabolic Engineering Platforms), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球合成生物学平台市场规模将达到 61.8 亿美元，在预测期内复合年增长率将达到 22.8%，到 2034 年将达到 320 亿美元。

合成生物学平台是一个整合了技术和计算科学的框架，旨在实现用于工业、医疗和环境应用的生物系统的设计、建构和最佳化。这些平台结合了基因工程、高通量筛检、自动化和生物资讯学，能够高精度、高效地创造新型生物体并改造现有生物体。透过快速原型製作基因迴路、代谢路径和生物分子原型，合成生物学平台加速了药物研发、农业、生质燃料和诊断领域的创新。其扩充性、模组化和可程式设计确保了实验的可重复性，降低了实验成本，并促进了从传统生物学转向设计型生物解决方案的转变。

对先进生物製药的需求不断成长

全球对创新生物製药日益增长的需求正在推动合成生物学平台的发展。随着精准医疗、基因疗法和个人化生物製药的兴起，企业需要能够高效设计和优化复杂生物系统的整合平台。这些平台能够加速药物发现进程、缩短研发週期并提高可重复性，从而满足人们对更安全、更有效疗法的日益增长的需求。因此，对先进生物製药的需求成为主要的成长要素，而合成生物学平台正逐渐成为生命科学领域不可或缺的工具。

监管复杂性和生物安全问题

儘管技术不断进步，合成生物学平台仍面临来自法律规范和生物安全要求的重大挑战。基因改造、环境释放和临床应用均有严格的指导方针，这往往导致研究和商业化进程的延迟。伦理考量、对生态系统的意外影响以及实验室安全问题进一步加剧了其应用推广的复杂性。合规需要大量的文件记录、测试和监测，这增加了操作的复杂性。这些监管和生物安全障碍是限制市场渗透的主要阻碍因素。

工具和平台的技术进步

基因编辑、自动化、高通量筛检和生物资讯学领域的持续创新为合成生物学平台带来了巨大的机会。基于CRISPR的新型工具和可扩展的生物反应器提高了生物技术的精确性和可重复性。这些进步加速了基因迴路和生物分子的原型製作，使其能够应用于製药、农业和环境解决方案等领域。随着技术的不断发展，平台变得更加模组化和易于使用，从而开拓了新的市场，并加速了其在生物技术、学术研究和产业界的普及应用。

高昂的初始成本和技术壁垒

建构合成生物学平台需要对先进的实验室基础设施和专用软体进行大量资金投入。此外，其技术复杂性要求具备设计、建模和建构人工生物系统能力的高技能人才。这些高昂的初始成本和知识门槛对中小企业而言构成了特别重大的准入障碍。此外，系统整合挑战、维护需求以及人才培养需求仍然是持续存在的难题，而高昂的成本和技术要求也对合成生物学平台的广泛应用构成了重大威胁。

新冠疫情的感染疾病：

新冠疫情凸显了快速生物技术创新的重要性，并加速了人们对合成生物学平台的关注。这些平台透过高通量筛检和基因工程加速了疫苗、治疗药物和诊断工具的研发。然而，供应链中断、实验室进入受限以及研究重点的调整暂时影响了研发进度。儘管面临这些挑战，疫情也凸显了扩充性和自动化平台的战略价值，促使人们加强长期投资并提高认知度。

在预测期内，生技公司细分市场预计将占据最大的市场份额。

由于药物发现和生物製造领域先进工具的广泛应用，预计生物技术公司将在预测期内占据最大的市场份额。这些公司利用整合平台优化基因迴路、扩大生产规模并加速创新流程。它们强大的研发基础设施、分子生物学专业知识以及对个人化医疗的专注，使其能够开发出高价值的应用。因此，生物技术公司保持领先的市场份额，并推动平台在製药和工业生物技术领域的应用。

在预测期内，基因编辑平台领域预计将呈现最高的复合年增长率。

在预测期内，基因编辑平台领域预计将呈现最高的成长率。这是因为整合了CRISPR和其他编辑技术的平台能够精确修改DNA序列，进而加速药物研发、农业和合成生物学领域的创新。个人化医疗、功能基因组学研究和工业生物技术等领域对基因编辑平台应用的日益增长的需求，是推动这一增长的主要动力。随着技术能力的提升，基因编辑平台将提供可重复的解决方案，使其成为整个合成生物学生态系统中成长最快的领域。

市占率最大的地区：

在预测期内，北美预计将占据最大的市场份额，这得益于其强大的生物技术生态系统、雄厚的研发投入以及政府的支持政策。主要企业的製药和生物技术公司、一流的研究机构以及完善的法规结构，都促进了相关技术的早期应用。基因组学、合成生物学和精准医疗领域的大量资金投入，正在加速创新。此外，学术机构和政府机构之间的合作正在推动平台开发，使北美成为区域市场的主导力量。

复合年增长率最高的地区：

在预测期内，由于政府对创新支持力度的加大，亚太地区预计将呈现最高的复合年增长率。合成生物学平台正在新兴市场迅速应用于药物研发、农业和工业生物技术等领域。精准医疗意识的不断提高，加上熟练研究人员数量的成长和成本优势，正在推动市场扩张。当地企业企业与全球企业之间的技术合作与伙伴关係进一步加速了合成生物学平台的应用，使亚太地区成为成长最快的区域市场。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章 全球合成生物学平台市场：按类型划分

  • DNA合成平台
  • 基因编辑平台
    • CRISPR
    • TALEN
    • ZFN
  • 蛋白质工程平台
  • 代谢工程平台

第六章 全球合成生物学平台市场：依应用划分

  • 医疗和药品
    • 药物发现
    • 基因治疗
  • 工业生物技术
    • 生质燃料
    • 生质塑胶
  • 农业和食品
    • 作物改良
    • 合成食品
  • 环境应用
    • 生物修復
    • 生物感测器

第七章 全球合成生物学平台市场：依最终用户划分

  • 学术研究机构
  • 生技公司
  • 製药公司
  • 政府和监管机构

第八章 全球合成生物学平台市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第九章 战略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十章：产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十一章：公司简介

  • Ginkgo Bioworks
  • Twist Bioscience
  • Amyris
  • Zymergen
  • Precigen
  • Genomatica
  • Codexis
  • Arzeda
  • Evolva
  • Novozymes
  • Thermo Fisher Scientific
  • Agilent Technologies
  • GenScript Biotech Corporation
  • Integrated DNA Technologies
  • Eurofins Scientific
Product Code: SMRC34665

According to Stratistics MRC, the Global Synthetic Biology Platforms Market is accounted for $6.18 billion in 2026 and is expected to reach $32.0 billion by 2034 growing at a CAGR of 22.8% during the forecast period. Synthetic Biology Platforms are integrated technological and computational frameworks that enable the design, construction, and optimization of biological systems for industrial, medical, and environmental applications. These platforms combine genetic engineering, high-throughput screening, automation, and bioinformatics to create novel organisms or modify existing ones with precision and efficiency. By facilitating rapid prototyping of genetic circuits, metabolic pathways, and biomolecules, synthetic biology platforms accelerate innovation in drug development, agriculture, biofuels, and diagnostics. Their scalable, modular, and programmable nature ensures reproducibility, reduces experimental costs, and drives the transition from traditional biology to engineered biological solutions.

Market Dynamics:

Driver:

Rising Demand for Advanced Biopharmaceuticals

The global push for innovative biopharmaceuticals is fueling the growth of synthetic biology platforms. As precision medicine, gene therapies, and personalized biologics gain prominence, companies require integrated platforms capable of designing and optimizing complex biological systems efficiently. These platforms accelerate drug discovery, reduce development timelines, and enhance reproducibility, meeting the increasing demand for safer, effective therapeutics. Consequently, the need for advanced biopharmaceuticals acts as a primary growth driver, positioning synthetic biology platforms as essential tools across the life sciences sector.

Restraint:

Regulatory Complexity and Biosafety Concerns

Despite technological advancements, synthetic biology platforms face significant challenges from regulatory frameworks and biosafety requirements. Stringent guidelines govern genetic modifications, environmental release, and clinical applications, often leading to delays in research and commercialization. Concerns around ethical considerations, unintended ecological impacts, and laboratory safety further complicate adoption. Compliance demands extensive documentation, testing, and oversight, increasing operational complexity. These regulatory and biosafety hurdles act as a major restraint, limiting market penetration.

Opportunity:

Technological Advancements in Tools and Platforms

Continuous innovation in gene editing, automation, high throughput screening, and bioinformatics presents immense opportunities for synthetic biology platforms. Novel CRISPR-based tools and scalable bioreactors enhance precision and reproducibility in biological engineering. These advancements allow faster prototyping of genetic circuits and biomolecules, enabling applications in pharmaceuticals, agriculture, and environmental solutions. As technology evolves, platforms become more modular and accessible and opening new markets and accelerating adoption across biotechnology, academic research, and industrial sectors.

Threat:

High Initial Costs and Technical Barriers

The deployment of synthetic biology platforms involves substantial capital investment in advanced laboratory infrastructure and specialized software. Additionally, technical complexity demands highly skilled personnel capable of designing, modeling, and implementing engineered biological systems. These high initial costs and knowledge barriers limit accessibility, particularly for small and mid-sized enterprises. Furthermore, integration challenges, maintenance requirements, and training demands pose ongoing hurdles, making cost and technical expertise critical threats that could impede broader adoption.

Covid-19 Impact:

The Covid-19 pandemic has underscored the importance of rapid biotechnological innovation, accelerating interest in synthetic biology platforms. These platforms enabled faster development of vaccines, therapeutics, and diagnostic tools through high-throughput screening and genetic engineering. However, disruptions in supply chains, laboratory access restrictions, and shifting research priorities temporarily affected R&D timelines. Despite these challenges, the pandemic highlighted the strategic value of scalable, automated platforms, boosting long-term investment and awareness.

The biotechnology companies segment is expected to be the largest during the forecast period

The biotechnology companies segment is expected to account for the largest market share during the forecast period, due to its extensive adoption of advanced tools for drug discovery and biomanufacturing. These companies leverage integrated platforms to optimize genetic circuits, scale up production, and accelerate innovation pipelines. Their robust R&D infrastructure, expertise in molecular biology, and focus on personalized therapeutics enable high-value applications. As a result, biotechnology companies maintain a leading market share, driving platform utilization across pharmaceuticals and industrial biotechnology initiatives.

The gene editing platforms segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the gene editing platforms segment is predicted to witness the highest growth rate, as platforms integrating CRISPR and other editing technologies allow precise modification of DNA sequences, enabling accelerated innovation in drug development, agriculture, and synthetic organisms. The increasing demand for personalized medicine, functional genomics studies, and industrial biotechnology applications fuels growth. As technological capabilities expand, gene editing platforms provide reproducible solutions, positioning this segment as the fastest-growing within the broader synthetic biology ecosystem.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to robust biotechnology ecosystem, strong R&D investment, and supportive government initiatives. The presence of leading pharmaceutical and biotech companies, cutting-edge research institutions, and well-established regulatory frameworks facilitates early adoption. Extensive funding for genomics, synthetic biology, and precision medicine accelerates innovation. Additionally, collaborations between academic and government entities drive platform development, making North America a dominant regional market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to increasing government support for innovation. Emerging economies are rapidly adopting synthetic biology platforms for pharmaceutical development, agriculture, and industrial biotechnology applications. Rising awareness of precision medicine, coupled with a growing pool of skilled researchers and cost advantages, enhances market expansion. Technological collaborations and partnerships between local and global players further accelerate adoption, positioning Asia Pacific as the fastest growing regional market.

Key players in the market

Some of the key players in Synthetic Biology Platforms Market include Ginkgo Bioworks, Twist Bioscience, Amyris, Zymergen, Precigen, Genomatica, Codexis, Arzeda, Evolva, Novozymes, Thermo Fisher Scientific, Agilent Technologies, GenScript Biotech Corporation, Integrated DNA Technologies and Eurofins Scientific.

Key Developments:

In July 2025, Thermo Fisher Scientific and Sanofi have deepened their long-standing alliance as Thermo Fisher acquires Sanofi's sterile drug manufacturing facility in Ridgefield, New Jersey, boosting U.S. drug production capacity and ensuring continued manufacture of key Sanofi therapies under an expanded strategic partnership.

In June 2025, Exum Instruments and Thermo Fisher Scientific have forged a strategic distribution partnership that brings Exum's Massbox(R) elemental analysis technology to Europe and China, leveraging Thermo Fisher's global network to expand access, support researchers, and accelerate materials and battery development workflows.

Types Covered:

  • DNA Synthesis Platforms
  • Gene Editing Platforms
  • Protein Engineering Platforms
  • Metabolic Engineering Platforms

Applications Covered:

  • Healthcare & Pharmaceuticals
  • Industrial Biotechnology
  • Agriculture & Food
  • Environmental Applications

End Users Covered:

  • Academic & Research Institutes
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Government & Regulatory Bodies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Synthetic Biology Platforms Market, By Type

  • 5.1 DNA Synthesis Platforms
  • 5.2 Gene Editing Platforms
    • 5.2.1 CRISPR
    • 5.2.2 TALEN
    • 5.2.3 ZFN
  • 5.3 Protein Engineering Platforms
  • 5.4 Metabolic Engineering Platforms

6 Global Synthetic Biology Platforms Market, By Application

  • 6.1 Healthcare & Pharmaceuticals
    • 6.1.1 Drug Discovery
    • 6.1.2 Gene Therapy
  • 6.2 Industrial Biotechnology
    • 6.2.1 Biofuels
    • 6.2.2 Bioplastics
  • 6.3 Agriculture & Food
    • 6.3.1 Crop Improvement
    • 6.3.2 Synthetic Foods
  • 6.4 Environmental Applications
    • 6.4.1 Bioremediation
    • 6.4.2 Biosensors

7 Global Synthetic Biology Platforms Market, By End User

  • 7.1 Academic & Research Institutes
  • 7.2 Biotechnology Companies
  • 7.3 Pharmaceutical Companies
  • 7.4 Government & Regulatory Bodies

8 Global Synthetic Biology Platforms Market, By Geography

  • 8.1 North America
    • 8.1.1 United States
    • 8.1.2 Canada
    • 8.1.3 Mexico
  • 8.2 Europe
    • 8.2.1 United Kingdom
    • 8.2.2 Germany
    • 8.2.3 France
    • 8.2.4 Italy
    • 8.2.5 Spain
    • 8.2.6 Netherlands
    • 8.2.7 Belgium
    • 8.2.8 Sweden
    • 8.2.9 Switzerland
    • 8.2.10 Poland
    • 8.2.11 Rest of Europe
  • 8.3 Asia Pacific
    • 8.3.1 China
    • 8.3.2 Japan
    • 8.3.3 India
    • 8.3.4 South Korea
    • 8.3.5 Australia
    • 8.3.6 Indonesia
    • 8.3.7 Thailand
    • 8.3.8 Malaysia
    • 8.3.9 Singapore
    • 8.3.10 Vietnam
    • 8.3.11 Rest of Asia Pacific
  • 8.4 South America
    • 8.4.1 Brazil
    • 8.4.2 Argentina
    • 8.4.3 Colombia
    • 8.4.4 Chile
    • 8.4.5 Peru
    • 8.4.6 Rest of South America
  • 8.5 Rest of the World (RoW)
    • 8.5.1 Middle East
      • 8.5.1.1 Saudi Arabia
      • 8.5.1.2 United Arab Emirates
      • 8.5.1.3 Qatar
      • 8.5.1.4 Israel
      • 8.5.1.5 Rest of Middle East
    • 8.5.2 Africa
      • 8.5.2.1 South Africa
      • 8.5.2.2 Egypt
      • 8.5.2.3 Morocco
      • 8.5.2.4 Rest of Africa

9 Strategic Market Intelligence

  • 9.1 Industry Value Network and Supply Chain Assessment
  • 9.2 White-Space and Opportunity Mapping
  • 9.3 Product Evolution and Market Life Cycle Analysis
  • 9.4 Channel, Distributor, and Go-to-Market Assessment

10 Industry Developments and Strategic Initiatives

  • 10.1 Mergers and Acquisitions
  • 10.2 Partnerships, Alliances, and Joint Ventures
  • 10.3 New Product Launches and Certifications
  • 10.4 Capacity Expansion and Investments
  • 10.5 Other Strategic Initiatives

11 Company Profiles

  • 11.1 Ginkgo Bioworks
  • 11.2 Twist Bioscience
  • 11.3 Amyris
  • 11.4 Zymergen
  • 11.5 Precigen
  • 11.6 Genomatica
  • 11.7 Codexis
  • 11.8 Arzeda
  • 11.9 Evolva
  • 11.10 Novozymes
  • 11.11 Thermo Fisher Scientific
  • 11.12 Agilent Technologies
  • 11.13 GenScript Biotech Corporation
  • 11.14 Integrated DNA Technologies
  • 11.15 Eurofins Scientific

List of Tables

  • Table 1 Global Synthetic Biology Platforms Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Synthetic Biology Platforms Market Outlook, By Type (2023-2034) ($MN)
  • Table 3 Global Synthetic Biology Platforms Market Outlook, By DNA Synthesis Platforms (2023-2034) ($MN)
  • Table 4 Global Synthetic Biology Platforms Market Outlook, By Gene Editing Platforms (2023-2034) ($MN)
  • Table 5 Global Synthetic Biology Platforms Market Outlook, By CRISPR (2023-2034) ($MN)
  • Table 6 Global Synthetic Biology Platforms Market Outlook, By TALEN (2023-2034) ($MN)
  • Table 7 Global Synthetic Biology Platforms Market Outlook, By ZFN (2023-2034) ($MN)
  • Table 8 Global Synthetic Biology Platforms Market Outlook, By Protein Engineering Platforms (2023-2034) ($MN)
  • Table 9 Global Synthetic Biology Platforms Market Outlook, By Metabolic Engineering Platforms (2023-2034) ($MN)
  • Table 10 Global Synthetic Biology Platforms Market Outlook, By Application (2023-2034) ($MN)
  • Table 11 Global Synthetic Biology Platforms Market Outlook, By Healthcare & Pharmaceuticals (2023-2034) ($MN)
  • Table 12 Global Synthetic Biology Platforms Market Outlook, By Drug Discovery (2023-2034) ($MN)
  • Table 13 Global Synthetic Biology Platforms Market Outlook, By Gene Therapy (2023-2034) ($MN)
  • Table 14 Global Synthetic Biology Platforms Market Outlook, By Industrial Biotechnology (2023-2034) ($MN)
  • Table 15 Global Synthetic Biology Platforms Market Outlook, By Biofuels (2023-2034) ($MN)
  • Table 16 Global Synthetic Biology Platforms Market Outlook, By Bioplastics (2023-2034) ($MN)
  • Table 17 Global Synthetic Biology Platforms Market Outlook, By Agriculture & Food (2023-2034) ($MN)
  • Table 18 Global Synthetic Biology Platforms Market Outlook, By Crop Improvement (2023-2034) ($MN)
  • Table 19 Global Synthetic Biology Platforms Market Outlook, By Synthetic Foods (2023-2034) ($MN)
  • Table 20 Global Synthetic Biology Platforms Market Outlook, By Environmental Applications (2023-2034) ($MN)
  • Table 21 Global Synthetic Biology Platforms Market Outlook, By Bioremediation (2023-2034) ($MN)
  • Table 22 Global Synthetic Biology Platforms Market Outlook, By Biosensors (2023-2034) ($MN)
  • Table 23 Global Synthetic Biology Platforms Market Outlook, By End User (2023-2034) ($MN)
  • Table 24 Global Synthetic Biology Platforms Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 25 Global Synthetic Biology Platforms Market Outlook, By Biotechnology Companies (2023-2034) ($MN)
  • Table 26 Global Synthetic Biology Platforms Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 27 Global Synthetic Biology Platforms Market Outlook, By Government & Regulatory Bodies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.